The weak side of sacubitril/valsartan in the treatment of heart failure

Studies with dual neprilysin-angiotensin receptor II inhibition of sacubitril/valsartan demonstrated positive results but only in heart failure patients with reduced ejection fraction. Valsartan, however, is not the only sartan, and enalapril is not the only or the best among the angiotensin-converting enzyme blockers. More on the video.

Leave your comment


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Notify of